<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00115206</url>
  </required_header>
  <id_info>
    <org_study_id>20020121</org_study_id>
    <nct_id>NCT00115206</nct_id>
  </id_info>
  <brief_title>Neulasta® in Subjects With Advanced Non-Small-Cell Lung Cancer (NSCLC) During Chemotherapy</brief_title>
  <official_title>A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to estimate the relationship between patient reported outcomes
      (PROs) and neutropenia (or its complications) in NSCLC subjects receiving chemotherapy with
      or without Neulasta® (pegfilgrastim).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date>July 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life, *Neutropenia, *Hospitalization, *Disease Response</measure>
  </secondary_outcome>
  <condition>Non-Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta® (pegfilgrastim)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Non-small cell lung cancer, not previously treated with chemotherapy
        or radiotherapy - ECOG performance status 0 or 1 - ANC greater than or equal to 2.0 x
        10^9/L Exclusion Criteria: - Cancer other than NSCLC within 5 years of enrollment, with the
        exception of surgically cured basal cell carcinoma or in situ carcinoma of the cervix -
        Treatment less than or equal to 30 days prior with any experimental agent - Subjects with
        symptomatic brain metastases - Subject is currently enrolled or has not yet completed at
        least 30 days since ending other investigational device or drug trial(s) or is receiving
        other investigational agent(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.neulasta.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2005</study_first_submitted>
  <study_first_submitted_qc>June 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2005</study_first_posted>
  <last_update_submitted>April 2, 2009</last_update_submitted>
  <last_update_submitted_qc>April 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Non Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Fever</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Neulasta®</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

